Preparation of orodispersible tablets of bosentan using xylitol and menthol as dissolution enhancers

Sci Rep. 2024 May 9;14(1):10680. doi: 10.1038/s41598-024-60494-9.


Bosentan is a drug used to treat pulmonary hypertension via dual endothelial receptor antagonism. Bosentan has a restricted oral bioavailability, a problem that's mostly due to poor solubility and hepatic metabolism. It is extensively used for the elderly and children who require a friendly dosage form like orodispersible tablets. So, the goal of this research work was to hasten the dissolution rate of bosentan to produce an orodispersible tablet with immediate drug release. Bosentan was exposed to ethanol-assisted kneading with a rise of xylitol or menthol concentrations (1:1 and 1:2 molar ratio of bosentan with excipient). In addition to observing the dissolution behavior, the resulting dry products were investigated using Fourier transform infrared spectroscopy (FTIR), differential thermal analysis (DTA), and X-ray diffraction (XRD). The FTIR reflected possible hydrogen bonding with xylitol and menthol. DSC studies reflected a reduction in the enthalpy and Tm. These results with XRD data reflected partial co-amorphization in the case of xylitol and eutaxia in the case of menthol. These modifications were related to an accelerated dissolving rate. The developed systems were fabricated as orodispersible tablets which exhibited immediate release of bosentan. Thus, the current study offered simple co-processing for the preparation of orodispersible bosentan tablets.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Bosentan* / chemistry
  • Calorimetry, Differential Scanning
  • Drug Compounding / methods
  • Drug Liberation
  • Excipients / chemistry
  • Humans
  • Menthol* / chemistry
  • Solubility*
  • Spectroscopy, Fourier Transform Infrared
  • Tablets*
  • X-Ray Diffraction
  • Xylitol* / chemistry


  • Bosentan
  • Xylitol
  • Tablets
  • Menthol
  • Excipients